Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Antidepressant costs and utilization are growing rapidly as newer selective serotonin reuptake inhibitors (SSRIs) comprise an ever-increasing share of the market. A number of factors and related costs must be considered when evaluating antidepressant products. An antidepressant drug utilization review study performed in two different HMO models revealed important variations among available SSRI therapies in terms of dosage escalation and discontinuation, as well as concomitant medication costs associated with treating side effects. New antidepressants may alleviate some of these problems.
Emron, Inc., Warren, NJ 07059, USA.
R
R
Navarro
W E
WE
Valler
M
M
Spangler
D015057:1-Naphthylamine / Q000031:analogs & derivatives; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000150:complications / Q000188:drug therapy / Q000191:economics; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D017723:Drug Utilization Review / Q000191:economics / Q000706:statistics & numerical data*; D005473:Fluoxetine; D006801:Humans; D008329:Managed Care Programs / Q000191:economics* / Q000458:organization & administration; D017146:Models, Organizational; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D014481:United States